



(51) International Patent Classification:

A61K 31/167 (2006.01) A61K 31/44 (2006.01)
A61K 31/4192 (2006.01)

(21) International Application Number:

PCT/US2014/030131

(22) International Filing Date:

17 March 2014 (17.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/804,412 22 March 2013 (22.03.2013) US

(71) Applicant: MERCK SHARP & DOHME CORP.
[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): ANDRESEN, Brian, M.
[US/US]; 33 Avenue Louis Pasteur, Boston, Massachusetts
02115-5727 (US). ANTHONY, Neville, J. [US/US]; 52
Lawrence Street, Northborough, Massachusetts 01532
(US). HAIDLE, Andrew, M. [US/US]; 33 Avenue Louis
Pasteur, Boston, Massachusetts 02115-5727 (US).
MILLER, Thomas, A. [US/US]; 18 Park Avenue, Wake-
field, Massachusetts 01880 (US). OSIMBONI, Ekundayo
[US/US]; 115 Algonquin Trail, Ashland, Massachusetts
01721 (US).

(74) Common Representative: MERCK SHARP & DOHME
CORP.; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS



(57) Abstract: The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

FIELD OF THE INVENTION

[0001] The present invention relates to certain 2-pyridyl carboxamide-containing compounds of the Formula (I) (also referred to herein as the “compounds of the Formula (I)” or “compounds of Formula (I)”) which are inhibitors of Spleen Tyrosine Kinase (Syk) kinase activity. The present invention also provides compositions comprising such compounds, and methods of using such compounds for treating conditions or disorders associated with inappropriate Syk activity, in particular in the treatment and prevention of disease states mediated by Syk. Such disease states may include inflammatory, allergic and autoimmune diseases, for example, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, idiopathic thrombocytopenic purpura (ITP), multiple sclerosis, cancer, HIV and lupus.

BACKGROUND OF THE INVENTION

[0002] Spleen Tyrosine Kinase (Syk) is a protein tyrosine kinase which has been described as a key mediator of immunoreceptor signalling in a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptors and the B-cell receptor, are important for both allergic diseases and antibody-mediated autoimmune diseases and thus pharmacologically interfering with Syk could conceivably treat these disorders.

[0003] Allergic rhinitis and asthma are diseases associated with hypersensitivity reactions and inflammatory events involving a multitude of cell types including mast cells, eosinophils, T cells and dendritic cells. Following exposure to allergen, high affinity immunoglobulin receptors for IgE and IgG become cross-linked and activate downstream processes in mast cells and other cell types leading to the release of pro-inflammatory mediators and airway spasmogens. In the mast cell, for example, IgE receptor cross-linking by allergen leads to release of mediators including histamine from pre-formed granules, as well as the synthesis and release of newly synthesized lipid mediators including prostaglandins and leukotrienes.

[0004] Syk kinase is a non-receptor linked tyrosine kinase which is important in transducing the downstream cellular signals associated with cross-linking Fc_{epsilon}RI and or

Fc_{epsilon}RI receptors, and is positioned early in the signalling cascade. In mast cells, for example, the early sequence of Fc_{epsilon}RI signalling following allergen cross-linking of receptor-IgE complexes involves first Lyn (a Src family tyrosine kinase) and then Syk. Inhibitors of Syk activity would therefore be expected to inhibit all downstream signalling cascades thereby alleviating the immediate allergic response and adverse events initiated by the release of pro-inflammatory mediators and spasmogens (Wong *et al.* 2004, *Expert Opin. Investig. Drugs* (2004) 13 (7) 743-762).

[0005] Recently, it has been shown that the Syk kinase inhibitor R112 (Rigel), dosed intranasally in a phase I/II study for the treatment of allergic rhinitis, gave a statistically significant decrease in PGD₂, a key immune mediator that is highly correlated with improvements in allergic rhinorrhea, as well as being safe across a range of indicators, thus providing the first evidence for the clinical safety and efficacy of a topical Syk kinase inhibitor. (Meltzer, Eli O.; Berkowitz, Robert B.; Grossbard, Elliott B. 2005, *Journal of Allergy and Clinical Immunology* 115(4): 791-796). In a more recent phase II clinical trial for allergic rhinitis (Clinical Trials.gov Identifier NCT0015089), R112 was shown as having a lack of efficacy versus placebo.

[0006] Rheumatoid Arthritis (RA) is an auto-immune disease affecting approximately 1% of the population. It is characterised by inflammation of articular joints leading to debilitating destruction of bone and cartilage. Recent clinical studies with Rituximab, which causes a reversible B cell depletion, (J. C. W. Edwards *et al.* 2004, *New Eng. J. Med.* 350: 2572-2581) have shown that targeting B cell function is an appropriate therapeutic strategy in auto-immune diseases such as RA. Clinical benefit correlates with a reduction in auto-reactive antibodies (or Rheumatoid Factor) and these studies suggest that B cell function and indeed auto-antibody production are central to the ongoing pathology in the disease.

[0007] Studies using cells from mice deficient in the Spleen Tyrosine Kinase (Syk) have demonstrated a non-redundant role of this kinase in B cell function. The deficiency in Syk is characterised by a block in B cell development (M. Turner *et al.* 1995 *Nature* 379: 298-302 and Cheng *et al.* 1995, *Nature* 378: 303-306). These studies, along with studies on mature B cells deficient in Syk (Kurasaki *et al.* 2000, *Immunol. Rev.* 176:19-29), demonstrate that Syk is required for the differentiation and activation of B cells. Hence, inhibition of Syk in RA patients is likely to block B cell function, and thereby reduce Rheumatoid Factor production. In addition to the role of Syk in B cell function, and of further relevance to the treatment of RA, is the requirement for Syk activity in Fc receptor (FcR) signalling. FcR activation by immune

complexes in RA has been suggested to contribute to the release of multiple pro-inflammatory mediators.


SUMMARY OF THE INVENTION

[0008] The present invention provides novel compounds that are potent inhibitors of Syk as well as pharmaceutical compositions containing them. As Syk inhibitors compounds of Formula (I) are useful in the treatment and prevention of diseases and disorders mediated by the Syk protein; such diseases and disorders include, but are not limited to, rheumatoid arthritis, asthma, COPD, cancer and idiopathic thrombocytopenic purpura.

DETAILED DESCRIPTION OF THE INVENTION


Compounds of the Invention

[0009] The present invention provides compound of Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined below. Described below are embodiments of the compound of Formula (I).



[0010] In embodiment no. 1 the present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of



R^3 is selected from the group consisting of methyl, methoxy, hydroxyl, pyridyl, and pyrazolyl, the subscript s is selected from the group consisting of 1, 2, or 3; and the compound is selected from the group consisting of:

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

(*R*)-3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((2,4-dimethyl-[3,3'-bipyridin]-6-yl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxopropan-2-yl)amino)picolinamide

3-([2,4'-bipyridin]-6-ylamino)-5-((2-amino-2-oxoethyl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxobutan-2-yl)amino)picolinamide Y;

(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide;

5-((2-amino-2-oxoethyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;

(*R*)-5-((1-amino-1-oxopropan-2-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;

(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide;

5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide; and

5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide.

[0011] In embodiment no. 2, the compound is selected from the group consisting of:

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

(*R*)-3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)amino)picolinamide; and

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((2,4-dimethyl-[3,3'-bipyridin]-6-yl)amino)picolinamide.

[0012] In embodiment no. 3, the compound is selected from the group consisting of:

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxopropan-2-yl)amino)picolinamide;
 3-([2,4'-bipyridin]-6-ylamino)-5-((2-amino-2-oxoethyl)amino)picolinamide;
 (*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)picolinamide;
 (*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxobutan-2-yl)amino)picolinamide Y;
 (*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide;
 5-((2-amino-2-oxoethyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;
 (*R*)-5-((1-amino-1-oxopropan-2-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide; and
 (*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide.

[0013] In embodiment no. 4, the compound is selected from the group consisting of:

5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide; and
 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide.

[0014] The invention also provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof in purified form.

Definitions

[0015] The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "hydroxyalkyl," "fluoroalkyl," "-O-alkyl," etc.

[0016] As used herein, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0017] A "patient" is a human or non-human mammal. In one embodiment, a patient is a human. In another embodiment, a patient is a chimpanzee.

[0018] The term "therapeutically effective amount" as used herein, refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a patient suffering from a disease or disorder mediated by Syk. In the combination therapies of the present invention, a therapeutically effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.

[0019] The term "preventing," as used herein with respect to a disease or disorder mediated by Syk, refers to reducing the likelihood of the occurrence of the disease or condition.

[0020] The term "alkyl," as used herein, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond having the specified number of carbon atoms. In different embodiments, an alkyl group contains from 1 to 6 carbon atoms (C₁-C₆ alkyl) or from 1 to 3 carbon atoms (C₁-C₃ alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched.

[0021] The term "alkoxy" as used herein, refers to an -O-alkyl group, wherein an alkyl group is as defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy. An alkoxy group is bonded via its oxygen atom.

[0022] The term "aryl," as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising from about 6 to about 14 carbon atoms. In one embodiment, an aryl group contains from about 6 to 10 carbon atoms (C₆-C₁₀ aryl). In another embodiment an aryl group is phenyl. Non-limiting examples of aryl groups include phenyl and naphthyl.

[0023] The term "cycloalkyl," as used herein, refers to a saturated ring containing the specified number of ring carbon atoms, and no heteroatom. In a like manner the term "C₃-C₆ cycloalkyl" refers to a saturated ring having from 3 to 6 ring carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0024] The term "halo," as used herein, means -F, -Cl, -Br or -I. In one embodiment, a halo group is -F or -Cl. In another embodiment, a halo group is -F.

[0025] The term "fluoroalkyl," as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a fluorine atom. In one embodiment, a fluoroalkyl group has from 1 to 6 carbon atoms. In another

embodiment, a fluoroalkyl group has from 1 to 3 carbon atoms. In another embodiment, a fluoroalkyl group is substituted with from 1 to 3 fluorine atoms. Non-limiting examples of fluoroalkyl groups include $\text{-CH}_2\text{F}$, -CHF_2 , and -CF_3 . The term "C₁-C₃ fluoroalkyl" refers to a fluoroalkyl group having from 1 to 3 carbon atoms.

[0026] The term "substituted" means that one or more hydrogens on the atoms of the designated are replaced with a selection from the indicated group, provided that the atoms' normal valencies under the existing circumstances are not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0027] When any substituent or variable occurs more than one time in any constituent or the compound of Formula (I), its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0028] The term "in purified form," as used herein, refers to the physical state of a compound after the compound is isolated from a synthetic process (*e.g.*, from a reaction mixture), a natural source, or a combination thereof. The term "in purified form," also refers to the physical state of a compound after the compound is obtained from a purification process or processes described herein or well-known to the skilled artisan (*e.g.*, chromatography, recrystallization and the like), in sufficient purity to be characterizable by standard analytical techniques described herein or well-known to the skilled artisan.

[0029] It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0030] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H₂O.

[0031] The compounds of Formula (I) may contain one or more stereogenic centers and can thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.

[0032] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (*e.g.*, chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (*e.g.*, hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (*e.g.*, substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.

[0033] It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.

[0034] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts and solvates of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the *IUPAC* 1974 Recommendations.

[0035] The compounds of Formula (I) can form salts which are also within the scope of this invention. Reference to a compound of Formula (I) herein is understood to include reference

to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (*i.e.*, non-toxic, physiologically acceptable) salts. Salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0036] Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,), xinafoates, and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl *et al*, Camille G. (eds.) *Handbook of Pharmaceutical Salts. Properties, Selection and Use*. (2002) Zurich: Wiley-VCH; S. Berge *et al*, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J. of Pharmaceutics* (1986) 33 201-217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; and in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.

[0037] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (*e.g.*, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (*e.g.*, dimethyl, diethyl, and dibutyl sulfates), long chain halides (*e.g.*, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (*e.g.*, benzyl and phenethyl bromides), and others.

[0038] The present invention further includes the compounds of Formula (I) in all their isolated forms. For example, the above-identified compounds are intended to encompass all forms of the compounds such as, any solvates, hydrates, stereoisomers, and tautomers thereof.

[0039] As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

[0040] In the compounds of generic Formula (I), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I). For example, different isotopic forms of hydrogen (H) include protium (^1H) and deuterium (^2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing *in vivo* half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Uses of the Compounds

[0041] Compounds of Formula (I) or its pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds can be used to treat or prevent a variety of conditions or diseases mediated by Spleen tyrosine kinase (Syk). Such conditions and diseases include, but are not limited to: (1) arthritis, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis and osteoarthritis; (2) asthma and other obstructive airways diseases, including chronic asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, adult respiratory distress syndrome, recurrent airway obstruction, and chronic obstruction pulmonary disease including emphysema; (3) autoimmune diseases or disorders, including those designated as single organ or single cell-type autoimmune disorders, for example Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia including idiopathic thrombopenic purpura, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, those designated as involving systemic autoimmune disorder, for example

systemic lupus erythematosus, immune thrombocytopenic purpura, rheumatoid arthritis, Sjogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid, and additional autoimmune diseases, which can be B-cell (humoral) based or T-cell based, including Cogan's syndrome, ankylosing spondylitis, Wegener's granulomatosis, autoimmune alopecia, Type I or juvenile onset diabetes, and thyroiditis; (4) cancers or tumors, including alimentary/gastrointestinal tract cancer, colon cancer, liver cancer, skin cancer including mast cell tumor and squamous cell carcinoma, breast and mammary cancer, ovarian cancer, prostate cancer, lymphoma and leukemia (including but not limited to acute myelogenous leukemia, chronic myelogenous leukemia, mantle cell lymphoma, NHL B cell lymphomas (*e.g.*, precursor B-ALL, marginal zone B cell lymphoma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt lymphoma, mediastinal large B-cell lymphoma), Hodgkin lymphoma, NK and T cell lymphomas; TEL-Syk and ITK-Syk fusion driven tumors) myelomas including multiple myeloma, myeloproliferative disorders kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma including oral and metastatic melanoma, Kaposi's sarcoma, proliferative diabetic retinopathy, and angiogenic-associated disorders including solid tumors, and pancreatic cancer; (5) diabetes, including Type I diabetes and complications from diabetes; (6) eye diseases, disorders or conditions including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis including uveitis associated with Behcet's disease and lens-induced uveitis, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmitis, allergic conjunctivitis, and ocular neovascularization; (7) intestinal inflammations, allergies or conditions including Crohn's disease and/or ulcerative colitis, inflammatory bowel disease, coeliac diseases, proctitis, eosinophilic gastroenteritis, and mastocytosis; (8) neurodegenerative diseases including motor neuron disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, or neurodegenerative disease caused by traumatic injury, stroke, glutamate neurotoxicity or hypoxia; ischemic/ reperfusion injury in stroke, myocardial ischemia, renal ischemia, heart attacks, cardiac hypertrophy, atherosclerosis and arteriosclerosis, organ hypoxia; (9) platelet aggregation and diseases associated with or caused by platelet activation, such as arteriosclerosis, thrombosis, intimal hyperplasia and restenosis following vascular injury; (10) conditions associated with cardiovascular diseases, including restenosis, acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary

thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, conditions requiring the fitting of prosthetic devices, and the like; (11) skin diseases, conditions or disorders including atopic dermatitis, eczema, psoriasis, scleroderma, pruritus and other pruritic conditions; (12) allergic reactions including anaphylaxis, allergic rhinitis, allergic dermatitis, allergic urticaria, angioedema, allergic asthma, or allergic reaction to insect bites, food, drugs, or pollen; (13) transplant rejection, including pancreas islet transplant rejection, bone marrow transplant rejection, graft- versus-host disease, organ and cell transplant rejection such as bone marrow, cartilage, cornea, heart, intervertebral disc, islet, kidney, limb, liver, lung, muscle, myoblast, nerve, pancreas, skin, small intestine, or trachea, and xeno transplantation; (14) low grade scarring including scleroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury, and post-myocardial infarction.

[0042] The invention thus provides compounds of Formula (I) and pharmaceutically acceptable salts thereof for use in therapy, and particularly in the treatment of diseases and conditions mediated by inappropriate Syk activity. The inappropriate Syk activity referred to herein is any Syk activity that deviates from the normal Syk activity expected in a particular patient. Inappropriate Syk activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of Syk activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation.

[0043] In a further embodiment, the present invention is directed to methods of regulating, modulating, or inhibiting Syk for the prevention and/or treatment of disorders related to unregulated Syk activity.

[0044] In a further embodiment, the present invention provides a method of treatment of a patient suffering from a disorder mediated by Syk activity, which comprises administering to said patient an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof. In a further embodiment, the present invention provides for the use of a compound of Formula (I), or a pharmaceutically

acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of a disorder mediated by Syk activity.

[0045] In a further embodiment said disorder is rheumatoid arthritis. In yet another embodiment, said disorder is cancer. In another embodiment, said disorder is systemic lupus erythematosus. In a further embodiment said disorder mediated by Syk activity is asthma. In a further embodiment said disorder is ocular conjunctivitis.

[0046] Yet another aspect of the present invention provides a method for treating diseases caused by or associated with Fc receptor signaling cascades, including FcεRI and/or FcγRI-mediated degranulation as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by and/or associated with the release or synthesis of chemical mediators of such Fc receptor signaling cascades or degranulation. In addition, Syk is known to play a critical role in immunotyrosine-based activation motif (ITAM) signaling, B cell receptor signaling, T cell receptor signaling and is an essential component of integrin beta (1), beta (2), and beta (3) signaling in neutrophils. Thus, compounds of the present invention can be used to regulate Fc receptor, ITAM, B cell receptor and integrin signaling cascades, as well as the cellular responses elicited through these signaling cascades. Non-limiting examples of cellular responses that may be regulated or inhibited include respiratory burst, cellular adhesion, cellular degranulation, cell spreading, cell migration, phagocytosis, calcium ion flux, platelet aggregation and cell maturation.

Compositions and Administration

[0047] While it is possible that, for use in therapy, a compound of Formula (I), as well as pharmaceutically acceptable salts thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the invention further provides a pharmaceutical composition, which comprises a compound of Formula (I) and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. The compounds of the Formula (I) and pharmaceutically acceptable salts thereof, are as described above. The carriers must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical composition including admixing a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers.

[0048] Pharmaceutical compositions of the present invention may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit

may contain, for example, 5 µg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound of the Formula (I), depending on the condition being treated, the route of administration and the age, weight and condition of the patient. Such unit doses may therefore be administered more than once a day. Preferred unit dosage compositions are those containing a daily dose or sub-dose (for administration more than once a day), as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical compositions may be prepared by any of the methods well known in the pharmacy art.

[0049] Pharmaceutical compositions of the present invention may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, topical, inhaled, nasal, ocular, or parenteral (including intravenous and intramuscular) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.

[0050] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the oral route, for treating, for example, rheumatoid arthritis.

[0051] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the nasal route, for treating, for example, allergic rhinitis.

[0052] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the inhaled route, for treating, for example, asthma, COPD or ARDS.

[0053] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the inhaled route, for treating, for example, asthma or COPD.

[0054] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the ocular route, for treating, diseases of the eye, for example, conjunctivitis.

[0055] In a further embodiment, the present invention provides a pharmaceutical composition adapted for administration by the parenteral (including intravenous) route, for treating, for example, cancer.

[0056] Pharmaceutical compositions of the present invention which are adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or

granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

[0057] For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

[0058] Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

[0059] Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and

compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

[0060] Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

[0061] Where appropriate, dosage unit compositions for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release, for example, by coating or embedding particulate material in polymers, wax or the like.

[0062] The compounds of Formula (I) and pharmaceutically acceptable salts thereof can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

[0063] The compounds of Formula (I) and pharmaceutically acceptable salts thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

[0064] Dosage forms for inhaled administration may conveniently be formulated as aerosols or dry powders.

[0065] For compositions suitable and/or adapted for inhaled administration, it is preferred that the compound or salt of Formula (I) is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation. The preferable

particle size of the size-reduced (*e.g.*, micronised) compound or salt or solvate is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).

[0066] Aerosol formulations, *e.g.*, for inhaled administration, can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.

[0067] Where the dosage form comprises an aerosol dispenser, it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a hydrofluorocarbon (HFC). Suitable HFC propellants include 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage forms can also take the form of a pump-atomiser. The pressurised aerosol may contain a solution or a suspension of the active compound. This may require the incorporation of additional excipients *e.g.*, co-solvents and/or surfactants to improve the dispersion characteristics and homogeneity of suspension formulations. Solution formulations may also require the addition of co-solvents such as ethanol. Other excipient modifiers may also be incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation.

[0068] For pharmaceutical compositions suitable and/or adapted for inhaled administration, it is preferred that the pharmaceutical composition is a dry powder inhalable composition. Such a composition can comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, the compound of Formula (I) or salt or solvate thereof (preferably in particle-size-reduced form, *e.g.*, in micronised form), and optionally a performance modifier such as L-leucine or another amino acid, and/or metals salts of stearic acid such as magnesium or calcium stearate. Preferably, the dry powder inhalable composition comprises a dry powder blend of lactose and the compound of Formula (I) or salt thereof. The lactose is preferably lactose hydrate *e.g.*, lactose monohydrate and/or is preferably inhalation-grade and/or fine-grade lactose. Preferably, the particle size of the lactose is defined by 90% or more (by weight or by volume) of the lactose particles being less than 1000 microns (micrometres) (*e.g.*, 10-1000 microns *e.g.*, 30-1000 microns) in diameter, and/or 50% or more of the lactose particles being less than 500 microns (*e.g.*, 10-500 microns) in diameter. More preferably, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 300 microns (*e.g.*, 10-300 microns, *e.g.*, 50-300 microns) in diameter, and/or 50% or more of the lactose particles being

less than 100 microns in diameter. Optionally, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 100-200 microns in diameter, and/or 50% or more of the lactose particles being less than 40-70 microns in diameter. It is preferable that about 3 to about 30% (*e.g.*, about 10%) (by weight or by volume) of the particles are less than 50 microns or less than 20 microns in diameter. For example, without limitation, a suitable inhalation-grade lactose is E9334 lactose (10% fines) (Borculo Domo Ingredients, Hanzeplein 25, 8017 J D Zwolle, Netherlands).

[0069] Optionally, in particular for dry powder inhalable compositions, a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (*e.g.*, containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device. The container is rupturable or peel-openable on demand and the dose of *e.g.*, the dry powder composition can be administered by inhalation via the device such as the DISKUS® device (GlaxoSmithKline). Other dry powder inhalers are well known to those of ordinary skill in the art, and many such devices are commercially available, with representative devices including Aerolizer® (Novartis), Airmax™ (IVAX), ClickHaler® (Innovata Biomed), Diskhaler® (GlaxoSmithKline), Accuhaler (GlaxoSmithKline), Easyhaler® (Orion Pharma), Eclipse™ (Aventis), FlowCaps® (Hovione), Handihaler® (Boehringer Ingelheim), Pulvinal® (Chiesi), Rotahaler® (GlaxoSmithKline), SkyeHaler™ or Certihaler™ (SkyePharma), Twisthaler (Merck), Turbuhaler® (AstraZeneca), Ultrahaler® (Aventis), and the like.

[0070] Dosage forms for ocular administration may be formulated as solutions or suspensions with excipients suitable for ophthalmic use.

[0071] Dosage forms for nasal administration may conveniently be formulated as aerosols, solutions, drops, gels or dry powders.

[0072] Pharmaceutical compositions adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurised aerosols, nebulizers or insufflators.

[0073] For pharmaceutical compositions suitable and/or adapted for intranasal administration, the compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof may be formulated as a fluid formulation for delivery from a fluid dispenser. Such fluid dispensers may have, for example, a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser. Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon

sequential pump actuations. The dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity. A fluid dispenser of the aforementioned type is described and illustrated in WO-A-2005/044354, the entire content of which is hereby incorporated herein by reference. The dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation. The housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing. A particularly preferred fluid dispenser is of the general type illustrated in FIGS. 30-40 of WO-A-2005/044354.

[0074] The following are examples of representative pharmaceutical dosage forms for the compounds of this invention:

<u>Injectable Suspension (I.M.)</u>	<u>mg/mL</u>
Compound of Formula (I)	10
Methylcellulose	5.0
Tween 80	0.5
Benzyl alcohol	9.0
Benzalkonium chloride	1.0
Water for injection to a total volume of 1 mL	

<u>Tablet</u>	<u>mg/tablet</u>
Compound of Formula (I)	25
Microcrystalline Cellulose	415
Providone	14.0
Pregelatinized Starch	43.5
Magnesium Stearate	2.5
	500

<u>Capsule</u>	<u>mg/capsule</u>
Compound of Formula (I)	25
Lactose Powder	573.5
Magnesium Stearate	1.5
	600

<u>Aerosol</u>	<u>Per canister</u>
Compound of Formula (I)	24 mg
Lecithin, NF Liquid Concentrate	1.2 mg
Trichlorofluoromethane, NF	4.025 gm
Dichlorodifluoromethane, NF	12.15 gm

[0075] It will be appreciated that when the compound of the present invention is administered in combination with other therapeutic agents normally administered by the inhaled, intravenous, oral or intranasal route, that the resultant pharmaceutical composition may be administered by the same routes.

[0076] It should be understood that in addition to the ingredients particularly mentioned above, the compositions may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

[0077] A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. However, an effective amount of a compound of Formula (I) for the treatment of diseases or conditions associated with inappropriate Syk activity, will generally be in the range of 5 µg to 100 mg/kg body weight of recipient (patient) per day and more usually in the range of 5 µg to 10 mg/kg body weight per day. This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, thereof, may be determined as a proportion of the effective amount of the compound of Formula (I) per se.

[0078] The compositions of the invention can further comprise one or more additional therapeutic agents, as discussed in further detail below. Accordingly, in one embodiment, the present invention provides compositions comprising: (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (ii) one or more additional therapeutic agents, that are not compounds of Formula (I); and (iii) a pharmaceutically acceptable carrier, wherein the amounts in the composition are together effective to treat one of the disease or conditions discussed above.

Combination Therapy

[0079] The compounds of Formula (I) or their pharmaceutically acceptable salts may be used in combination, either in a single formulation or co-administered as separate formulations with at least one additional therapeutic agent to treat or prevent the diseases and conditions described herein. These additional therapeutic agents include, but are not limited to: (1) a DP receptor antagonist, such as S-5751 and laropiprant; (2) a corticosteroid, such as triamcinolone acetonide, budesonide, beclomethasone, fluticasone and mometasone; (3) a β 2-adrenergic agonist, such as salmeterol, formoterol, arformoterol, terbutaline, metaproterenol, albuterol and the like; (4) a leukotriene modifier, including a leukotriene receptor antagonist, such as montelukast, zafirlukast, pranlukast, or a lipoxygenase inhibitor including 5-lipoxygenase inhibitors and FLAP (5-lipoxygenase activating protein) inhibitors, such as zileuton; (5) an antihistamine such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleminamine, hydroxyzine, methdilazine, promethazine, trimепразин, azatadine, cyproheptadine, antazoline, pheniramine pyriline, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (6) a decongestant, including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; (7) an antitussive, including codeine, hydrocodone, caramiphen, carbetapentane, or dexamethorphan; (8) another prostaglandin ligand, including prostaglandin F agonist such as latanoprost; misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; (9) a diuretic; (10) non-steroidal antiinflammatory agents (NSAIDs), such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, mioprofen, naproxen, oxaprozin, piroprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (11) cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; (12) inhibitors of phosphodiesterase type IV (PDE-IV) *e.g.*, Ariflo, roflumilast; (13) antagonists of the chemokine receptors, especially CCR-1, CCR-2, and CCR-3; (14) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin

and pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzaifibrate), and probucol; (15) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α -glucosidase inhibitors (acarbose) and glitazones (troglitazone, pioglitazone, englitazone, rosiglitazone and the like); (16) preparations of interferon beta (interferon beta-1a, interferon beta-1b); (17) anticholinergic agents, such as muscarinic antagonists (ipratropium bromide and tiotropium bromide), as well as selective muscarinic M3 antagonists; (18) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (19) triptans commonly used for the treatment of migraine such as sumatriptan and rizatriptan; (20) alendronate and other treatments for osteoporosis; (21) other compounds such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, cytotoxic cancer chemotherapeutic agents, bradykinin (BK2) antagonists such as FK-3657, TP receptor antagonists such as seratrovast, neurokinin antagonists (NK1/NK2), VLA-4 antagonists, such as those described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96/20216, WO96/01644, WO96/06108, WO95/15973 and WO96/31206. In addition, the invention encompasses a method of treating prostaglandin D2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula (I), optionally co-administered with one or more of such ingredients as listed immediately above.

[0080] When administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like.

[0081] In one embodiment, the compound of Formula (I) is administered during a time when the additional therapeutic agent(s) exert their prophylactic or therapeutic effect, or *vice versa*.

[0082] In another embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder.

[0083] In another embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder.

[0084] In one embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.

[0085] The compound of Formula (I) and the additional therapeutic agent(s) can act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.

[0086] The doses and dosage regimen of the additional therapeutic agent(s) used in the combination therapies of the present invention for the treatment or prevention of a disease or disorder can be determined by the attending clinician, taking into consideration the approved doses and dosage regimen in the package insert; the age, sex and general health of the patient; and the type and severity of the viral infection or related disease or disorder.

[0087] Another aspect of this invention is a kit comprising a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt of said compound, optionally at least one additional therapeutic agent listed above and a pharmaceutically acceptable carrier, vehicle or diluent.

Methods of Preparing the Compounds of Formula (I)

[0088] The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the Formula (I) are prepared in the Examples.

[0089] Compounds of general Formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991) *Protecting Groups in Organic Synthesis*, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of protecting groups as well as the reaction conditions and order of reaction steps shall be consistent with the preparation of compounds of Formula (I). Those skilled in the art will recognize whether a stereocenter exists in compounds of Formula (I). Accordingly, the present invention includes all possible stereoisomers and includes not only mixtures of stereoisomers (such as racemic compounds) but the individual stereoisomers as well. When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate.

Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).

[0090] The following solvents, reagents, protecting groups, moieties, and other designations may be referred to by their abbreviations in parenthesis:

[0091] Me = methyl; Et = ethyl; Pr = propyl; iPr = isopropyl, Bu = butyl; t-Bu = tert-butyl; Ph = phenyl, and Ac = acetyl

[0092] μ l = microliters

[0093] AcOH or HOAc = acetic acid

[0094] ACN = acetonitrile

[0095] Ad = adamantyl

[0096] aq = aqueous

[0097] Bn = benzyl

[0098] Boc or BOC = *tert*-butoxycarbonyl

[0099] Bz = benzoyl

[00100] Cbz = benzyloxycarbonyl

[00101] DBa = dibenzylideneacetone

[00102] DBU = 1,8-Diaza-7-bicyclo[5.4.0]undecene

[00103] DCM = dichloromethane

[00104] DMAP = 4-Dimethylaminopyridine

[00105] DIBAL = diisobutylaluminum hydride

[00106] DIEA or Hünig's Base = N,N-diisopropylethylamine

[00107] DMA = 1,2-dimethylacetamide

[00108] DMF = dimethylformamide

[00109] DMSO = dimethyl sulfoxide

[00110] Dppf = 1,1'-Bis(diphenylphosphino)ferrocene

[00111] DMT = Dimercaptotriazine

[00112] DTT = dithiothreitol

[00113] EDTA = ethylenediamine tetraacetic acid

[00114] ESI = Electrospray ionization

[00115] EtOAc = ethyl acetate

[00116] g = grams

[00117] GST = glutathione S-transferase


[00118] h = hour

- [00119] HMDS = 1,1,1,3,3,3-hexamethyldisilazane
- [00120] HATU = N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate
- [00121] HPLC = high-performance liquid chromatography
- [00122] HOBt = 1-hydroxybenzotriazole
- [00123] LDA = lithium diisopropylamide
- [00124] LC = liquid chromatography
- [00125] LCMS = liquid chromatography mass spectrometry
- [00126] min = minute
- [00127] mg = milligrams
- [00128] mL = milliliters
- [00129] mmol = millimoles
- [00130] Me = methyl
- [00131] MeOH = methanol
- [00132] MS = mass spectrometry
- [00133] NBS = N-bromosuccinimide
- [00134] NMP = N-methylpyrrolidone
- [00135] NMR = nuclear magnetic resonance spectroscopy
- [00136] *rac* = racemic mixture
- [00137] RT or rt = room temperature (ambient, about 25 °C)
- [00138] sat = saturated
- [00139] SFC = supercritical fluid chromatography
- [00140] TBSCl = t-butyldimethylsilyl chloride
- [00141] TBS = t-butyldimethylsilyl
- [00142] TEA = triethylamine (Et₃N)
- [00143] TFA = trifluoroacetic acid
- [00144] TFAA = trifluoroacetic anhydride
- [00145] THF = tetrahydrofuran
- [00146] TLC = thin layer chromatography
- [00147] TMS = trimethylsilyl
- [00148] Tris = tris(hydroxymethyl)aminomethane
- [00149] Xantphos = 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene

General Methods

[00150] Compounds of the Formula (I) can be prepared according to one of the methods described in the Examples below. The compounds exemplified are illustrative of the invention and are not, however, to be construed as limiting the scope of the invention in any manner. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of protecting groups, of reagents, as well as of the conditions and processes of the following preparative procedures, can be used to prepare these compounds. It is also understood that whenever a chemical reagent is not commercially available, such a chemical reagent can be readily prepared by those skilled in the art by either following or adapting known methods described in the literature. All temperatures are degrees Celsius unless otherwise noted. Mass spectra (MS) were measured either by electrospray ion-mass spectroscopy (ESMS) or by atmospheric pressure chemical ionization mass spectroscopy (ESI).

[00151] For ease of reference, various moieties are referred in the Examples below as "A" moieties, "B" moieties, and the "pyridylcarboxamide" moiety. These moieties are illustrated in the structural formula below.




[00152] The starting materials and reagents used in preparing compounds described are either available from commercial suppliers or were prepared by literature methods known to those skilled in the art.

[00153] These examples are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby.

EXAMPLES

Preparative Example 1 – Preparation of Pyridylcarboxamide Precursors


Preparative Example 1.1 - *tert*-butyl {(1*S*,2*R*)-2-[(5-bromo-6-cyanopyridin-3-yl)amino]cyclohexyl}carbamate



[00154] *Tert*-butyl [(1*S*,2*R*)-2-aminocyclohexyl]carbamate (purchased from Small Molecules, Inc. (CAS: 365996-30-1, Hoboken, New Jersey). DIPEA (18.5 mL, 106 mmol) and *tert*-butyl [(1*S*,2*R*)-2-aminocyclohexyl]carbamate (17.7 g, 82.7 mmol) were added to 3-bromo-5-fluoropyridine-2-carbonitrile (Frontier Scientific; CAS: 950670-18-5, Logan, Utah) (16.4 g, 81.6 mmol) dissolved in NMP (16.3 mL) in a 150 mL sealed tube. The reaction was heated to 120°C for 24 hours before cooling to ambient temperature. Hydrochloric acid (1.0 M in water, 100 mL, 100 mmol) was added. Dichloromethane was then added dropwise until a freely stirring suspension was formed. The precipitate was collected by filtration, washed with cold diethyl ether (30 mL), and dried under reduced pressure to afford a portion of *tert*-butyl {(1*S*,2*R*)-2-[(5-bromo-6-cyanopyridin-3-yl)amino]cyclohexyl}carbamate. The mother liquors were separated and the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with diethyl ether and water to yield an additional portion of *tert*-butyl {(1*S*,2*R*)-2-[(5-bromo-6-cyanopyridin-3-yl)amino]cyclohexyl}carbamate. MS ESI calc'd. for C₁₇H₂₄BrN₄O₂ [M + H]⁺ 395 and 397, found 395 and 397. ¹H NMR (500 MHz, CD₃OD) δ 8.02 (d, *J* = 2.3 Hz, 1H), 7.23 (br s, 1H), 6.59 – 6.46 (m, 1H), 3.83 (s, 1H), 1.65 (s, 6H), 1.56 – 1.17 (m, 11H).

Preparative Example 2 – Preparation of B Moiety Precursors


Preparative Example 2.1 - 6-(2*H*-1,2,3-triazol-2-yl)pyridin-2-amine



[00155] 6-Chloropyridin-2-amine (2.00 g, 15.6 mmol) and 1*H*-1,2,3-triazole (3.22 g, 46.7 mmol) were combined in a 75 mL sealed flask and heated overnight at 180°C. The reaction mixture was cooled to room temperature, and diluted with DCM and a solution of saturated aqueous ammonium chloride. The organics were dried over sodium sulfate, filtered, and


concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-50% acetone in hexanes, linear gradient) to afford a 1:1 mixture of 1*H* and 2*H* triazole regioisomers. Further purification by HPLC afforded the separated regioisomers (15-30% acetonitrile/water with 0.1% ammonium hydroxide, linear gradient). MS ESI calc'd. for $C_7H_8N_5$ $[M + H]^+$ 162, found 162. 1H NMR (2*H* isomer, 500 MHz, DMSO- d_6) δ 8.03 (s, 2H), 7.56 (t, $J = 7.9$ Hz, 1H), 7.03 (d, $J = 7.6$ Hz, 1H), 6.46 (d, $J = 8.1$ Hz, 1H), 6.39 (s, 2H).

Preparative Example 2.2 - 2,4-dimethyl-[3,3'-bipyridin]-6-amine



[00156] Step 1: To a flask was added 4,6-dimethylpyridin-2-amine (12.2 g, 100 mmol), periodic acid (3.87 g, 17 mmol) and iodine (10.4 g, 41 mmol). Acetic acid (100 mL), water (20 mL) and H_2SO_4 (3 mL) were then added, and the reaction was heated to 80 °C for a period of 1.5 h, after which time the reaction was cooled to rt and water (10 mL) and heptanes (50 mL) were added. The layers were separated and the aqueous phase was extracted with heptanes (50 mL). The aqueous phase was concentrated under reduced pressure, and then EtOAc (150 mL) and water (5 mL) were added. To this mixture was added 8 M NaOH (3 x 20 mL portions), and then the layers were separated. The organic phase was washed with saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride and then dried (Na_2SO_4), filtered and concentrated under reduced pressure to an orange solid. The solid was slurried in EtOAc (45 mL) and then filtered to yield 5-iodo-4,6-dimethylpyridin-2-amine (14.2 g, 95%) as a white solid. MS ESI calcd. for $C_7H_9IN_2$ 249, found 249.


[00157] Step 2: To a flask was added 5-iodo-4,6-dimethylpyridin-2-amine (8.46 g, 34 mmol), toluene (30 mL), acetonylacetone (4.8 mL, 41 mmol), and TsOH monohydrate (52 mg, 0.27 mmol). The flask was fitted with a Dean-Stark trap and external heat set to 150 °C was applied for a period of 7 h, after which time the reaction was cooled to rt. The mixture was concentrated under reduced pressure and then purified by silica gel chromatography using a solvent system of DCM/hexanes to furnish 6-(2,5-dimethyl-1*H*-pyrrol-1-yl)-3-iodo-2,4-dimethylpyridine (8.0 g, 72%) as a white solid. MS ESI calcd. for $C_{13}H_{15}IN_2$ 327, found 327. 1H NMR (500 MHz, $CDCl_3$) δ 6.89 (s, 1H), 5.88 (s, 2H), 2.81 (s, 3H), 2.50 (s, 3H), 2.12 (s, 6H).



[00158] Step 3: To a flask was added 6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-iodo-2,4-dimethylpyridine (200 mg, 0.61 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (189 mg, 0.92 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (50 mg, 0.06 mmol), sodium carbonate (130 mg, 1.2 mmol), 1,4-dioxane (2.5 mL) and water (0.6 mL), and then nitrogen was bubbled through the reaction for a period of 5 min, after which time the reaction was sealed and heated under microwave irradiation at a temperature of 160 °C for a period of 30 min. After cooling to rt, the mixture was diluted with EtOAc, filtered, and then concentrated to furnish 6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4-dimethyl-3,3'-bipyridine (170 mg, 100%) which was used in the next transformation without further purification. MS ESI calcd. for C₁₈H₁₉N₃ 278, found 278.

[00159] Step 4: To a microwave vial was added 6-(2,5-dimethyl-1H-pyrrol-1-yl)-2,4-dimethyl-3,3'-bipyridine (170 mg, 0.61 mmol), hydroxylamine hydrochloride (426 mg, 10 eq), TEA (0.17 mL, 1.2 mmol), EtOH (2 mL) and water (1 mL), and then the mixture was sealed and heated at a temperature of 90 °C for a period of 16 h. The reaction was then cooled to rt and diluted with saturated aqueous sodium bicarbonate, saturated aqueous sodium carbonate, and 10% IPA/CHCl₃. The layers were separated, and the aqueous phase was extracted with 10% IPA/CHCl₃. The combined organic phases were washed with saturated aqueous sodium chloride, dried (Na₂SO₄), filtered, and concentrated under reduced pressure. Chromatography on silica using a solvent system of MeOH/DCM furnished 2,4-dimethyl-[3,3'-bipyridin]-6-amine (112 mg, 92). MS ESI calcd. for C₁₂H₁₃N₃ 200, found 200. ¹H NMR (500 MHz, DMSO-d₆) δ 8.51 (d, *J* = 4.4, 1H), 8.35 (s, 1H), 7.59 (d, *J* = 7.0, 1H), 7.42 (dd, *J* = 7.5, 4.9, 1H), 6.21 (s, 1H), 5.84 (s, 2H), 1.95 (s, 3H), 1.82 (s, 3H).


Preparative Example 2.3 - 5-methoxy-4,6-dimethylpyridin-2-amine



[00160] Step 1: To a microwave vial was added 6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-iodo-2,4-dimethylpyridine (362 mg, 1.0 mmol), 1,10-phenanthroline (72 mg, 0.4 mmol), CuI (38 mg, 0.2 mmol), and Cs₂CO₃ (489 mg, 1.5 mmol) and the mixture was vacuum-purged with argon 5x. Degassed toluene (1.25 ml) and degassed MeOH (0.61 mL) were added, the reaction was flushed with argon, sealed and heated under microwave irradiation at 160 °C for a period of 4 h, after which time the mixture was cooled to rt, diluted with EtOAc, filtered and concentrated under reduced pressure. Chromatography on silica using a solvent system of EtOAc/hexanes furnished 6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy-2,4-dimethylpyridine (183 mg, 80%). MS ESI calcd. for C₁₄H₁₈N₂O 231, found 231.


[00161] Step 2: To a microwave vial was added 6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-methoxy-2,4-dimethylpyridine (183 mg, 0.80 mmol), hydroxylamine hydrochloride (553 mg, 8.0 mmol), TEA (0.22 mL, 1.6 mmol) and water (0.8 mL) and the mixture was heated to 90 °C for a period of 16 h, after which time the reaction was cooled to rt and diluted with saturated aqueous sodium bicarbonate, saturated aqueous sodium carbonate, and 10% IPA/CHCl₃. The layers were separated, and the aqueous phase was extracted with 10% IPA/CHCl₃ (3x). The combined organic phases were washed with saturated aqueous sodium chloride, dried Na₂SO₄, filtered and concentrated under reduced pressure. Chromatography on silica using a solvent system of MeOH/DCM furnished 5-methoxy-4,6-dimethylpyridin-2-amine (109 mg, 90%). MS ESI calcd. for C₈H₁₂N₂O 153, found 153. ¹H NMR (500 MHz, CDCl₃) δ 6.19 (s, 1H), 4.13 (s, 2H), 3.65 (s, 3H), 2.35 (s, 3H), 2.19 (d, *J* = 0.5, 3H).

Preparative Example 2.4 - 5-(benzyloxy)-4,6-dimethylpyridin-2-amine



[00162] 5-(Benzyloxy)-4,6-dimethylpyridin-2-amine was prepared using methods similar to those described in Preparative Example 2.3. MS ESI calcd. for $C_{14}H_{16}N_2O$ 229, found 229.


Preparative Example 2.5 - 4-methoxy-6-methylpyridin-2-amine



[00163] Step 1: A suspension of 4,6-dichloropyridin-2-amine (1.63 g, 10 mmol), methylboronic acid (0.6 g, 10 mmol), Cs_2CO_3 (9.75 g, 30 mmol), and $Pd(dppf)Cl_2$ (400 mg) in dioxane/water (4:1, 50 mL) was stirred for 18 hours at 100 °C. The reaction was diluted with water and extracted with EtOAc (50 mLx3). The combined organic layer was washed with water and brine. The resulting solution was concentrated under reduced pressure and the residue was purified via prep-HPLC to afford 4-chloro-6-methylpyridin-2-amine (100 mg) as brown solid. MS ESI calcd. For $C_6H_7ClN_2$ $[M + H]^+$ 143, found 143.


[00164] Step 2: A suspension of 4-chloro-6-methylpyridin-2-amine (284 mg, 2 mmol) in DMSO (10 mL) was added sodium methanolate (540 mg, 10 mmol), and the resulting mixture was then stirred for 18 hours at 140 °C. The reaction was filtered and the filtrate was purified via prep-HPLC to afford 4-methoxy-6-methylpyridin-2-amine (110 mg) as brown solid. MS ESI calcd. For $C_7H_{10}N_2O$ $[M + H]^+$ 139, found 139.

Preparative Example 2.6 - 4-methyl-[2,4'-bipyridin]-6-amine



[00165] A suspension of 6-bromo-4-methylpyridin-2-amine (300 mg, 1.59 mmol), pyridin-4-ylboronic acid (196 mg, 1.59 mmol), Cs_2CO_3 (1.55g, 4.77mmol), and $Pd(dppf)Cl_2$ (100 mg) in dioxane/water (4:1, 25 mL) was stirred for 12 hours at 120 °C. The reaction was then filtered and the filtrate was purified via column chromatography on silica gel (petroleum ether/EtOAc=5:1) to give 4-methyl-[2,4'-bipyridin]-6-amine (250 mg) as brown solid. MS ESI calcd. For $C_{11}H_{11}N_3$ $[M + H]^+$ 186, found 186.


Preparative Example 2.7 - [2,4']bipyridinyl-6-ylamine



[00166] A suspension of 6-bromo-pyridin-2-ylamine (300 mg, 1.73 mmol), pyridin-4-ylboronic acid (213 mg, 1.73 mmol), Cs_2CO_3 (1.68 g, 5.19 mmol), and $\text{Pd}(\text{dppf})\text{Cl}_2$ (100 mg) in dioxane/water (4:1, 25 mL) was stirred for 12 hours at 120 °C. The reaction was then filtered and the filtrate was purified by column chromatography on silica gel (petroleum ether/EtOAc=5:1) to give [2,4']bipyridinyl-6-ylamine (220 mg) as brown solid. MS ESI calcd. For $\text{C}_{10}\text{H}_9\text{N}_3$ $[\text{M} + \text{H}]^+$ 172, found 172.

Preparative Example 3 – Preparation of A Moiety Precursors


Preparative Example 3.1 - 2-amino-3-hydroxy-propionamide



[00167] A suspension of 2-amino-3-hydroxy-propionic acid methyl ester hydrochloride (3 g, 19 mmol) in 10 % ammonia solution in MeOH (25 mL) was stirred in a seal-tube for 18 hours at 100 °C. The reaction was then concentrated to give 2-amino-3-hydroxy-propionamide (1.8 g) as white solid. MS ESI calcd. For $\text{C}_3\text{H}_9\text{ClN}_2\text{O}_2$ $[\text{M} + \text{H}]^+$ 141, found 141.

Example 1

Example 1.1 – Preparation of (R)-3-(((6-(2H-1,2,3-Triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide



1.1

[00168] **Step 1:** To a solution of 6-(2H-1,2,3-triazol-2-yl)pyridin-2-amine (4.90 g, 30.4 mmol) in THF (50 mL) was added KHMDS (6.37 g), and the reaction became heterogeneous. After 5 min, 5-bromo-3-fluoropicolinonitrile (6.42 g, 31.9 mmol, Manchester Organics, Ltd.; CAS: 886373-28-0, Runcorn, UK)) was added, and the mixture was heated to 60 °C for a period


of 1 h, after which time the reaction was cooled to rt and a 1:1 mixture of water:saturated aqueous ammonium chloride was added. The resulting slurry was filtered, and then the solid was collected and slurried in a mixture of EtOAc and hexanes. Filtration furnished 3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-bromopicolinonitrile (4.0 g, 38.5%) as a white solid. ^1H NMR (600 MHz, DMSO- d_6) δ 9.84 (s, 1H), 9.18 (s, 1H), 8.45 (s, 1H), 8.13 (s, 2H), 7.92 (t, J = 8.0, 1H), 7.53 (d, J = 7.8, 1H), 7.20 (d, J = 8.1, 1H).

[00169] Step 2: To a microwave vial was added 3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-bromopicolinonitrile (50 mg, 0.15 mmol), D-leucinamide (19 mg, 0.15 mmol), $\text{Pd}_2(\text{dba})_3$ (13 mg, 0.015 mmol), and CsF (56 mg, 0.37 mmol). The vial was vacuum purged with argon 3x, and then 1,4-dioxane (0.7 mL) was added. The mixture was heated to 90 °C for a period of 16 h and then cooled to rt. The mixture was concentrated under reduced pressure, dissolved in DMSO, filtered, and purified by reverse phase HPLC using a mobile phase of MeCN/water modified with 0.1% TFA. The product-containing fractions were diluted with EtOAc and washed with saturated aqueous sodium bicarbonate. The organic phase was washed with saturated aqueous sodium chloride and then dried over anhydrous MgSO_4 . Filtration followed by concentration under reduced pressure furnished (R)-2-((5-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-6-cyanopyridin-3-yl)amino)-4-methylpentanamide (57 mg, 100%) as a colorless film. MS ESI calcd. for $\text{C}_{19}\text{H}_{21}\text{N}_9\text{O}$ $[\text{M} + \text{H}]^+$ 392, found 392.

[00170] Step 3: To a solution of (R)-2-((5-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-6-cyanopyridin-3-yl)amino)-4-methylpentanamide (57 mg, 0.146 mmol) in DMSO (1.5 mL) was added 4 M NaOH (0.18 mL, 0.73 mmol), and then an aqueous solution of H_2O_2 (30%, 0.15 mL, 1.5 mmol) was added dropwise. The resulting slurry was stirred for 3 h and then diluted with EtOAc, washed with saturated aqueous sodium bicarbonate, dried over anhydrous MgSO_4 , filtered and concentrated under reduced pressure. The product was purified by reverse phase HPLC using a solvent system of MeCN/water modified with 0.1% TFA. Product-containing fractions were collected, diluted with EtOAc, washed with saturated aqueous sodium bicarbonate, dried (MgSO_4), filtered and concentrated under reduced pressure to yield (R)-3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide (19 mg, 32%) as a colorless film. MS ESI calcd. for $\text{C}_{19}\text{H}_{23}\text{N}_9\text{O}_2$ $[\text{M} + \text{H}]^+$ 410, found 410. ^1H NMR (600 MHz, DMSO- d_6) δ 11.89 (s, 1H), 9.32 (d, J = 2.1, 1H), 8.60 (d, J = 2.1, 1H), 8.29 (s, 1H), 8.11 (s, 2H), 7.90 (t, J = 8.0, 1H), 7.75 (s, 1H), 7.48 (d, J = 7.8, 1H), 7.04 (d, J = 8.1, 1H), 3.34 (dd, J = 9.3, 5.0, 1H), 2.96 (s, 2H), 1.83 – 1.73 (m, 1H), 1.51 (ddd, J = 13.5, 8.7, 5.0, 1H), 1.40 – 1.30 (m, 1H), 0.90 (d, J = 6.6, 3H), 0.87 (d, J = 6.6, 3H).

Example 2

Example 2.1 – Preparation of 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide



[00171] Step 1: To a microwave vial was added 5-methoxy-4,6-dimethylpyridin-2-amine (50 mg, 0.33 mmol), tert-butyl ((1*S*,2*R*)-2-((5-bromo-6-cyanopyridin-3-yl)amino)cyclohexyl)carbamate (130 mg, 0.33 mmol), Xantphos (29 mg, 0.049 mmol), Pd₂(dba)₃ (21 mg, 0.023 mmol), Cs₂CO₃ (268 mg, 0.82 mmol), and 1,4-dioxane (1.5 mL) and the vial was vacuum purged with argon 5x. The reaction was then heated to 80 °C for a period of 2.5 h. The reaction was then cooled to rt and Quadrapure TU resin (0.5 g, 0.1 mmol) and EtOAc (2 mL) were added. The mixture was then stirred for a period of 16 h, after which time the reaction was filtered, washed with saturated aqueous sodium bicarbonate and then saturated aqueous sodium chloride. The organic phase was dried (Na₂SO₄), filtered and concentrated under reduced pressure. Purification by silica gel chromatography using a solvent system of EtOAc/hexanes furnished tert-butyl ((1*S*,2*R*)-2-((6-cyano-5-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)pyridin-3-yl)amino)cyclohexyl)carbamate (118 mg, 77%). MS ESI calcd. for C₂₅H₃₄N₆O₃ [M + H]⁺ 467, found 467.


[00172] Step 2: To a solution of tert-butyl ((1*S*,2*R*)-2-((6-cyano-5-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)pyridin-3-yl)amino)cyclohexyl)carbamate (118 mg, 0.25 mmol) in DCM (2.5 mL) was added TFA (0.5 mL, 6.49 mmol) and the solution was stirred for 40 min, after which time toluene (1 mL) was added and the mixture was concentrated under reduced pressure. MeOH (1 mL) and toluene (1 mL) were added and the reaction was concentrated under reduced pressure to yield 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-

dimethylpyridin-2-yl)amino)picolinonitrile (93 mg, 100%), which was used without further purification. MS ESI calcd. for $C_{20}H_{26}N_6O$ $[M + H]^+$ 367, found 367.

[00173] Step 3: To a solution of 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinonitrile (93 mg, 0.25 mmol) in DMSO (2 mL) was added KOH (71 mg, 1.3 mmol) and aqueous H_2O_2 (35%, 0.22 mL, 2.54 mmol) and the reaction was stirred at rt. After 30 minutes, additional KOH (71 mg, 1.3 mmol) and aqueous H_2O_2 (35%, 0.22 mL, 2.54 mmol) were added, and the reaction was stirred for an additional 1.5 h at rt. After this time, the mixture was filtered, diluted with DMSO, and purified by reverse phase HPLC using a solvent system of MeCN/water modified with 0.1% TFA. The product-containing fractions were diluted with saturated aqueous sodium bicarbonate (20 mL), saturated aqueous sodium carbonate (10 mL), saturated aqueous sodium chloride (30 mL), and 10% IPA/ $CHCl_3$ (30 mL). The layers were separated and the aqueous phase was extracted with 10% IPA/ $CHCl_3$ (2x20 mL). The combined organic phases were dried (Na_2SO_4), filtered and concentrated under reduced pressure to yield 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide (57 mg, 58%) as a white solid. MS ESI calcd. for $C_{20}H_{28}N_6O_2$ $[M + H]^+$ 385, found 385. 1H NMR (500 MHz, DMSO- d_6) δ 11.62 (s, 1H), 8.43 (d, $J = 2.4$, 1H), 7.81 (s, 1H), 7.58 (d, $J = 2.5$, 1H), 7.19 (s, 1H), 6.52 (s, 1H), 6.19 (d, $J = 7.2$, 1H), 3.62 (s, 3H), 3.20 – 3.09 (m, 1H), 2.35 (s, 3H), 2.19 (s, 3H), 1.83 – 1.39 (m, 8H), 1.39 – 1.23 (m, 2H).

Example 3

Example 3.1 – Preparation of 5-(((1*R*,2*S*)-2-Aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide



[00174] Step 1: To a flask was added tert-butyl ((1*S*,2*R*)-2-((5-bromo-6-cyanopyridin-3-yl)amino)cyclohexyl)carbamate (260 mg, 0.66 mmol), 5-(benzyloxy)-4,6-dimethylpyridin-2-amine (225 mg, 0.99 mmol), Xantphos (76 mg, 0.13 mmol), Pd₂(dba)₃ (60 mg, 0.066 mmol), and Cs₂CO₃ (643 mg, 2.0 mmol) and nitrogen was bubbled through the mixture for 5 min. The reaction was then heated at 80 °C for a period of 16 h, after which time the reaction was cooled to rt, diluted with EtOAc, filtered, concentrated under reduced pressure, and purified by silica gel chromatography using a solvent system of EtOAc and hexanes to furnish tert-butyl ((1*S*,2*R*)-2-((5-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)-6-cyanopyridin-3-yl)amino)cyclohexyl)carbamate (282 mg, 79%). MS ESI calcd. for C₃₁H₃₈N₆O₃ [M + H]⁺ 543, found 543.


[00175] Step 2: To a solution of tert-butyl ((1*S*,2*R*)-2-((5-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)-6-cyanopyridin-3-yl)amino)cyclohexyl)carbamate (62 mg, 0.11 mmol) in DCM (2 mL) was added TFA (0.5 mL, 6.5 mmol), and the reaction was stirred for a period of 1 h, after which time the mixture was concentrated under reduced pressure to yield 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)picolinonitrile (51 mg, 100%). MS ESI calcd. for C₂₆H₃₀N₆O [M + H]⁺ 443, found 443.

[00176] Step 3: To a solution of 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)picolinonitrile (51 mg, 0.12 mmol) in DMSO (2 mL) was added aqueous H₂O₂ (35%, 0.10 mL, 1.2 mmol) and 4 M NaOH (0.14 mL, 0.58 mmol) and the reaction was stirred at rt for 30 min. Water was added, and the resulting slurry was filtered. The solid was washed with water (3x) then dissolved in DMSO and purified by reverse phase HPLC to yield 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)picolinamide (35 mg, 66%). MS ESI calcd. for C₂₆H₃₂N₆O₂ [M + H]⁺ 461, found 461.

[00177] Step 4: A solution of 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-(benzyloxy)-4,6-dimethylpyridin-2-yl)amino)picolinamide (35 mg, 0.076 mmol) in MeOH (2 mL) was purged with nitrogen (5x) and then with hydrogen (5x), and then the reaction was subjected to balloon-pressure hydrogen for a period of 2 h, after which time the mixture was diluted with DCM and filtered. Concentration under reduced pressure yielded 5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide (29 mg, 79%). MS ESI calcd. for C₁₉H₂₆N₆O₂ [M + H]⁺ 371, found 371. ¹H NMR (500 MHz, CD₃OD) δ 7.79 (d, *J* = 2.4, 1H), 7.54 (s, 1H), 7.08 (s, 1H), 4.02 – 3.87 (m, 1H), 3.66 – 3.49 (m, 1H), 2.48 (s, 3H), 2.34 (s, 3H), 1.96 – 1.82 (m, 3H), 1.82 – 1.64 (m, 3H), 1.64 – 1.48 (m, 2H).

Example 4

Example 4.1 – Preparation of (*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide




[00178] **Step 1:** A suspension of 3-bromo-5-fluoropicolinonitrile (500 mg, 2.5 mmol) and (*R*)-2-amino-4-methylpentanamide hydrochloride (325 mg, 2.5 mmol) and DIPEA (967 mg, 7.5 mmol) in NMP (10 mL) was stirred for 4 hours at 100 °C. The reaction was diluted with water (20 mL) and extracted with EtOAc (20 mLx3). The combined organic layer was washed with water and brine. The resulting solution was concentrated under reduce pressure and purified via column chromatography on silica gel (petroleum ether/EtOAc=1:1) to afford (*R*)-2-((5-bromo-6-cyanopyridin-3-yl)amino)-4-methylpentanamide (650 mg) as white solid. MS ESI calcd. For $C_{12}H_{15}BrN_4O$ $[M + H]^+$ 312, found 312.















[00179] **Step 2:** A suspension of (*R*)-2-((5-bromo-6-cyanopyridin-3-yl)amino)-4-methylpentanamide (160 mg, 0.51 mmol) and 4-methyl-[2,4'-bipyridin]-6-amine (115 mg, 0.62 mmol), Xantphos (91 mg, 0.16 mmol), Cs_2CO_3 (546 mg, 1.68 mmol) and $Pd_2(dba)_3$ (60 mg) in dioxane (10 mL) was stirred for 4 hours at 95 °C. The reaction was then diluted with water and extracted with EtOAc. The organic layers were washed with brine and concentrated under reduce pressure. The residue was purified via column chromatography on silica gel (petroleum ether/EtOAc=1:1) to afford (*R*)-2-((6-cyano-5-((4-methyl-[2,4'-bipyridin]-6-yl)amino)pyridin-3-yl)amino)-4-methylpentanamide (40 mg) as light yellow solid. MS ESI calcd. For $C_{23}H_{25}N_7O$ $[M + H]^+$ 416, found 416.

[00180] Step 3: A suspension of (*R*)-2-((6-cyano-5-((4-methyl-[2,4'-bipyridin]-6-yl)amino) pyridin-3-yl)amino)-4-methylpentanamide (40 mg, 0.1 mmol) and K₂CO₃ (27.6 mg, 0.2 mmol), H₂O₂ (0.1 mL) in DMSO (4 mL) was stirred for 2 hours at room temperature. The mixture was then filtered and the filtrate was purified via prep-HPLC to give (*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide (10 mg) as white solid. MS ESI calcd. For C₂₃H₂₇N₇O₂ [M + H]⁺ 434, found 434. ¹H NMR (CD₃OD, 400 MHz) δ 8.87 (d, *J*=6.26 Hz, 2 H), 8.60 (d, *J*=6.26 Hz, 2 H), 8.25 (d, *J*=2.34 Hz, 1 H), 7.68 (d, *J*=2.34 Hz, 1 H), 7.56 (s, 1 H), 6.75 (s, 1 H), 3.81-3.86 (m, 1 H), 2.35 (s, 3 H), 1.77-1.88 (m, 1 H), 1.70-1.77 (m, 2 H), 0.97 (d, *J*=6.26 Hz, 3 H), 0.86 (d, *J*=6.26 Hz, 3 H).

[00181] The following compounds were prepared according to procedures which were analogous to those described in Example 4.1. In the preparation of the some of the compounds in the table, Pd(OAc)₂ was used in place of Pd₂(dba)₃ in the coupling reaction of step 2.



Ex. No.	A	B	Name	[M+H] ⁺ Calc'd	[M+H] ⁺ Obsv'd	Form(s)
4.2			(<i>R</i>)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide	387	387	TFA salt
4.3			3-([2,4'-bipyridin]-6-ylamino)-5-((2-amino-2-oxoethyl)amino)picolinamide	364	364	TFA salt
4.4			(<i>R</i>)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxopropan-2-yl)amino)picolinamide	378	378	TFA salt

4.5			(R)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxobutan-2-yl)amino)picolinamide	392	392	TFA salt
4.6			(R)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)picolinamide	394	394	TFA salt
4.7			5-((2-amino-2-oxoethyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide	315	315	Free base
4.8			(R)-5-((1-amino-1-oxopropan-2-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide	329	329	Free base
4.9			(R)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide	420	420	Free base
4.10			racemic-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)amino)picolinamide	411	411	Free base
4.11			racemic-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((2,4-dimethyl-[3,3'-bipyridin]-6-yl)amino)picolinamide	448	448	Free base

BIOLOGICAL ASSAY**Homogeneous Time-Resolved Fluorescence (HTRF) Assay For The Recombinant Human Syk Enzyme**

[00182] A recombinant GST-hSYK fusion protein was used to measure potency of compounds to inhibit human Syk activity. The recombinant human GST-SYK (Carna Biosciences #08-176) (5 pM final concentration) was incubated with various concentrations of the inhibitor diluted in DMSO (0.1% final concentration) for 10 minutes at room temperature in 15 mM Tris-HCl (pH 7.5), 0.01% tween 20, 2 mM DTT in 384 well plate format. To initiate the reaction the biotinylated substrate peptide (250 nM final concentration) that contains the phosphorylation site for Syk was added with magnesium (5 mM final concentration) and ATP (25 μ M final concentration). Final volume of the reaction was 10 μ L. Phosphorylation of the peptide was allowed to proceed for 45 minutes at room temperature. To quench the reaction and detect the phosphorylated product, 2 nM of a Europium-anti-phosphotyrosine antibody (Perkin Elmer #AD0161) and 70 nM SA-APC (Perkin-Elmer #CR130-100) were added together in 15 mM Tris pH 7.5, 40 mM EDTA, 0.01% tween 20. Final volume of the quenching solution was 10 μ L. The resulting HTRF signal was measured after 30 minutes on an EnVision (Perkin-Elmer) reader using a time-resolved fluorescence protocol. IC₅₀ was determined following 10-dose titration (10 μ M to 0.508 nM) and four parameter logistic curve fitting using an assay data analyzer. Table 1 below lists the IC₅₀ values for representative compounds of the invention.

Table 1

Example No.	rhSYK Activity (nM)
1.1	165.9
2.1	<0.5
3.1	<0.5
4.1	<0.5
4.2	4.661
4.3	23.9
4.4	1.685

Example No.	rhSYK Activity (nM)
4.5	0.9712
4.6	1.65
4.7	80.59
4.8	7.669
4.9	<0.5
4.10	1.415
4.11	3.887

[00183] While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of:

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

(*R*)-3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((2,4-dimethyl-[3,3'-bipyridin]-6-yl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxopropan-2-yl)amino)picolinamide

3-([2,4'-bipyridin]-6-ylamino)-5-((2-amino-2-oxoethyl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)picolinamide;

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxobutan-2-yl)amino)picolinamide Y;

(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide;

5-((2-amino-2-oxoethyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;

(*R*)-5-((1-amino-1-oxopropan-2-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;

(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide ;

5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide; and

5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 selected from the group consisting of:

(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

(*R*)-3-((6-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)amino)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)picolinamide;

5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)amino)picolinamide; and
5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((2,4-dimethyl-[3,3'-bipyridin]-6-yl)amino)picolinamide;
or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 selected from the group consisting of:
(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxopropan-2-yl)amino)picolinamide;
3-([2,4'-bipyridin]-6-ylamino)-5-((2-amino-2-oxoethyl)amino)picolinamide;
(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)picolinamide;
(*R*)-3-([2,4'-bipyridin]-6-ylamino)-5-((1-amino-1-oxobutan-2-yl)amino)picolinamide Y;
(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methyl-[2,4'-bipyridin]-6-yl)amino)picolinamide;
5-((2-amino-2-oxoethyl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide;
(*R*)-5-((1-amino-1-oxopropan-2-yl)amino)-3-((4,6-dimethylpyridin-2-yl)amino)picolinamide; and
(*R*)-5-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-((4-methoxy-6-methylpyridin-2-yl)amino)picolinamide;
or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 selected from the group consisting of:
5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-methoxy-4,6-dimethylpyridin-2-yl)amino)picolinamide; and
5-(((1*R*,2*S*)-2-aminocyclohexyl)amino)-3-((5-hydroxy-4,6-dimethylpyridin-2-yl)amino)picolinamide;
or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5, further comprising an additional therapeutic agent.

7. A method of treating a disease or condition mediated by spleen tyrosine kinase (Syk) comprising administering a therapeutically effective amount of the compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof.
8. The method of claim 7, wherein the disease or condition mediated by Syk is rheumatoid arthritis.
9. The method of claim 7, wherein the disease or condition mediated by Syk is asthma.
10. The method of claim 7, wherein the disease or condition mediated by Syk is systemic lupus erythematosus.
11. Use of a compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof, for treating a disease or condition mediated by spleen tyrosine kinase (Syk).

INTERNATIONAL SEARCH REPORT

014/030131 28.07.2014

International application No.

PCT/US14/30131

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/167, 31/4192, 31/44 (2014.01)

USPC - 514/235.5, 318, 359

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/166, 31/167, 31/4192, 31/44; C07D 211/00, 213/127, 249/04 (2014.01)

USPC - 514/93, 235.5, 259.3, 318, 359; 548/255

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); Google; Google Scholar; PubMed; IP.com; therapeutically effective amount, therapeutic agent, spleen tyrosine kinase, Syk, rheumatoid arthritis, asthma, systemic lupus erythematosus, pyridine, amino, methyl, amino, picolinamide, methoxy

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2012/0142671 A1 (JIA, ZJ et al.) June 07, 2012; abstract; paragraphs [0008], [0016], [0184], [0214], [0245], [0267], [0317], [0345]-[0346], [0360]-[0361], [1121]-[1122]; claims 57, 59	1-4, 5/1-4, 6/5/1-4, 7/1-4, 8/7/1-4, 9/7/1-4, 10/7/1-4, 11/1-4
Y	WO 2010/086646 A1 (SHUTTLE-WORTH, SJ et al.) August 05, 2010; page 11, lines 4-5; page 21, lines 14-20, formula	1-2, 5/1-2, 6/5/1-2, 7/1-2, 8/7/1-2, 9/7/1-2, 10/7/1-2, 11/1-2
Y	WO 2010/010184 A1 (MENET, CJM et al.) January 28, 2010; paragraphs [00303]-[00304], [00513], [00798]-[00804]	1-4, 5/1-4, 6/5/1-4, 7/1-4, 8/7/1-4, 9/7/1-4, 10/7/1-4, 11/1-4
Y	WO 02/32900 A2 (NAKAO, K et al.) April 25, 2002; page 1, lines 6-8; page 106, line 1	1, 3-4, 5/1, 5/3-4, 6/5/1, 6/5/3-4, 7/1, 7/3-4, 8/7/1, 8/7/3-4, 9/7/1, 9/7/3-4, 10/7/1, 10/7/3-4, 11/1, 11/3-4
Y	KYTTARIS, VC et al., Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus, Current Opinion on Rheumatology, September 2011, Vol. 23, No. 5, pp. 449-453 [online], [retrieved on 2014-06-27]. Retrieved from the Internet <URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158574/ > <DOI: 10.1097/BOR.0b013e328349a242>; abstract	10/7/1-4
A	WO 2011/029537 A1 (LUCKING, U et al.) March 17, 2011; entire publication	1-4, 5/1-4, 6/5/1-4, 7/1-4, 8/7/1-4, 9/7/1-4, 10/7/1-4, 11/1-4

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 July 2014 (05.07.2014)

Date of mailing of the international search report

28 JUL 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774